Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a prevalent, complex, and multifactorial endocrine disorder that affects a significant proportion of women of reproductive age. Characterized by irregular menstrual cycles, hyperandrogenism, and polycystic ovaries, PMOS is more than just a reproductive condition—it is a multisystem disorder with far-reaching consequences for metabolic, psychological, and overall health [1]. PMOS develops when genetic elements and hormonal disturbances and environmental stressors jointly interrupt ovarian operations and cause sex hormone unbalance and insulin resistance.  PMOS marks a persistent complicated multisystem disease which impacts between 8 and 13 percent of adult females in their reproductive years and 3 to 11 percent of teenage girls according to research and diagnostic variables [2]. A worldwide acceptance connects the diagnostic tools from the European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) consensus Rotterdam criteria with the Rotterdam ESHRE/ASRM-Sponsored PMOS Consensus Workshop Group 2004. The diagnosis of PMOS in adults requires two out of three features that include oligo/amenorrhoea (OA) and clinical/biochemical hyperandrogenism (HA) and polycystic ovary morphology (PCOM) seen under ultrasound after ruling out secondary causes (Rotterdam ESHRE/ASRM-Sponsored PMOS Consensus Workshop Group 2004). The 2018 International PMOS guideline removes the requirement for PCOM investigation from the diagnosis of adolescence while maintaining the need for both OA and HA criteria [3].

PMOS manifests as a diverse disorder which affects people differently depending on their age. The condition shows initial signs during childhood which then evolves into health impacts during adolescence along with adult stages of life. PMOS has significant metabolic (obesity, metabolic syndrome, impaired glucose tolerance, type 2 diabetes, cardiovascular risk factors), reproductive (anovulation, subfertility, pregnancy complications), dermatological (acne, hirsutism, alopecia) and psychological (depression, anxiety, eating disorders, impaired quality of life) sequelae [4].While understanding that HA and insulin resistance are the key pathophysiological drivers of PMOS, the underlying aetiology, primarily the genetics’ and epigenetics’ contribution to various disease pathways, remains largely unclear. The unclear origins of specific PMOS cases have slowed down the creation of specific medications for treating women with this condition. The clinical challenges for PMOS diagnosis include its diverse presentation alongside differences within patients' symptoms and changing manifestations during developmental periods [5].

Clinical practice differs across countries and medical specialities due to a lack of medical training and cohesive clinical guidelines leading to unsatisfactory healthcare and poor health outcomes in women with PMOS. Polyendocrine Metabolic Ovarian Syndrome (PMOS) is increasingly recognized as a multisystem disorder, extending beyond the reproductive system and affecting multiple bodily systems. While PMOS is primarily considered a reproductive condition due to its impact on ovarian function, it is associated with a range of hormonal imbalances that influence various health aspects [6]. Elevated androgens, such as testosterone, contribute to symptoms like irregular periods, acne, and excessive hair growth. Moreover, insulin resistance is common in PMOS, increasing the risk of developing metabolic conditions such as Type 2 diabetes, obesity, and metabolic syndrome. These metabolic issues also pose significant cardiovascular risks, as women with PMOS often experience high blood pressure, high cholesterol, and a greater likelihood of heart disease. Additionally, the physical manifestations of PMOS, including weight gain, acne, and hair loss, can significantly affect mental health, leading to higher rates of depression, anxiety, and eating disorders. Fertility challenges, such as difficulty conceiving and increased risk of miscarriage, are also common, adding another layer of complexity to the condition. Beyond reproductive health, women with PMOS face long-term health risks, including a higher likelihood of endometrial cancer, non-alcoholic fatty liver disease, and other complications due to hormonal imbalances [7].

Reproductive health is often the most prominent concern for women with PMOS, particularly in terms of fertility and menstrual irregularities. One of the hallmark features of PMOS is hormonal imbalance, particularly elevated levels of androgens, or male hormones, such as testosterone. These elevated levels can disrupt the normal function of the ovaries, leading to irregular or absent ovulation. Ovulation is crucial for fertility, as it is the process through which a mature egg is released from the ovary, making it available for fertilization by sperm. Without regular ovulation, conceiving becomes more difficult, and infertility is a common concern among women with PMOS [8].

Many women with PMOS experience menstrual irregularities, including infrequent or absent periods. These irregular cycles can make it challenging to predict fertile windows, further complicating conception efforts. In some cases, women may have a condition known as "anovulation," in which the ovaries fail to release eggs altogether, contributing to the lack of menstruation. This can result in prolonged periods without a menstrual cycle, which can be frustrating for those trying to conceive. In addition to fertility issues, women with PMOS are at an increased risk of pregnancy complications. Studies have shown that women with PMOS are more likely to experience miscarriage, preterm birth, and gestational diabetes. These complications are often related to the underlying hormonal imbalances and insulin resistance associated with PMOS. Managing these risks requires a thorough understanding of the individual's reproductive health and close monitoring throughout pregnancy [9].

Causes and Pathophysiology

The condition of PMOS creates both high levels of male hormones and irregular menstrual cycles which cannot be attributed to any other medical issue. Otherwise no other condition exists to explain the symptoms thus PMOS must be diagnosed. This condition represents the main cause among hyperandrogenic presentations. PMOS develops from functional ovarian hyperandrogenism in almost all patients who have this condition. The typical functional ovarian hyperandrogenism presents in two-thirds of PMOS patients through abnormal androgen production that exhibits high 17-hydroxyprogesterone (17-OHP) output after gonadotropin stimulation. PMOS patients with abnormal FOH present increased testosterone levels which become detectable when their adrenal androgen production is suppressed. The third percent of PMOS patients exhibit an isolated functional hyperandrogenism condition in their adrenal glands. The mild form accounts for other cases of PMOS. Studies show no steroid dysfunction in this group but obesity remains the main characteristic of these patients according to medical practitioners. Present-day clinical settings have limited diagnostic value when it comes to testing the FOH subpopulation. [10]

The main characteristics of Functional ovarian hyperandrogenism PMOS include hyperandrogenism and oligo anovulation as well as polycystic ovary morphology. The development of functional ovarian hyperandrogenism results from multiple origins including inherited and environmental elements. Insulin excess leads to luteinizing hormone sensitivity in the ovaries by disrupting natural luteinizing hormone desensitization during typical menstrual cycles while creating imbalances between ovarian regulatory systems. Research shows that steroidogenic enzyme and protein overexpression in Theca cells of women with PMOS indicates substantial abnormalities concerning enzyme levels particularly P450c17 where significant evidence exists. Studies show that premature luteinization occurs mainly due to elevated levels of androgen and insulin in the system [11]. The process of premature luteinization begins while interfering with the selection of dominant follicles. The condition leads to classic PMOS pathologic and visible changes known as polycystic ovarian morphology (PCOM). About 1-half of patients with functional ovarian hyperandrogenism have an abnormal degree of insulin-resistant hyperinsulinism, which acts on theca cell, increasing steroidogenesis prematurely, luteinizes granulosa cells, and stimulates fat accumulation [12]. Hyperandrogenemia provokes LH excess, which then acts on theca and luteinized granulosa sustaining cycle. Ovarian hormonal dysregulation alters the pulsatile gonadotropin-releasing hormone release, potentially leading to a relative increase in LH versus follicle-stimulating hormone (FSH) biosynthesis and secretion. LH stimulates ovarian androgen production, while the relative decrease of FSH prevents adequate stimulation of aromatase activity within the granulosa cells, decreasing androgen conversion to the potent estrogen estradiol. This becomes a self-perpetuating, noncyclic hormonal pattern. Elevated serum androgens are converted in the periphery to estrogens, mostly estrone. As conversion occurs primarily in the stromal cells of adipose tissue, estrogen production is augmented in obese PMOS patients. This conversion results in chronic feedback at the hypothalamus and pituitary gland, in contrast to the normal fluctuations in feedback observed in the presence of a growing follicle and rapidly changing estradiol levels. Unopposed estrogen stimulation of the endometrium may lead to endometrial hyperplasia.[11][12][13].

Interconnected Mechanisms

• Insulin resistance → ↑ Increased androgens → increasedreproductive dysfunction
• Obesity → ↑increased inflammation → ↑increased psychological distress
• Psychological stress → worsens hormonal imbalance

Genetic and Epigenetic Factors:

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a common endocrine disorder that is influenced by both genetic and epigenetic factors. Genetic predisposition plays a significant role in the development of PMOS, as the condition tends to run in families, suggesting a hereditary component. Several candidate genes have been linked to PMOS, such as the FSHR (Follicle-Stimulating Hormone Receptor) and LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor) genes, which affect ovarian function and hormonal balance. Additionally, genes involved in insulin signaling, such as insulin receptor genes, contribute to the insulin resistance commonly seen in PMOS. Genome-wide association studies (GWAS) have identified various loci associated with PMOS, including genes related to ovarian function and inflammation, such as DENND1A and THADA [14]. Epigenetic factors also play a crucial role in the condition. DNA methylation, histone modifications, and microRNA dysregulation can alter gene expression without changes to the DNA sequence itself. Environmental factors like diet, obesity, and exposure to endocrine-disrupting chemicals can influence these epigenetic modifications, potentially increasing the risk of developing PMOS. Moreover, the intrauterine environment, such as maternal obesity during pregnancy, can lead to epigenetic changes in offspring that predispose them to PMOS later in life. It is believed that genetic factors provide a foundation for the disorder, but environmental influences may trigger epigenetic changes that modify the severity or onset of symptoms [15].

Research has detected promoter conservation within LHCGR alongside THADA and DENND1A alongside multiple other genes. [3–6]. Luteinizing hormone/chorionic gonadotropic receptors (LHCGR) exist in theca and mature granulosa cells of adult ovaries while polymorphisms that occur within LHCGR boost androgen production [7]. DENND1A encodes for DENN proteins with overexpression also driving excess ovarian steroidogenesis [8]. The absence of distinct heritable data pointing to one cause of PMOS caused researchers to investigate elements which affect gene expression patterns. Dumesic et al. demonstrated that maternal insulin resistance increases hyperinsulinemia exposure to the fetus who develops abnormal levels of ovarian steroidogenesis resulting in excessive production of androgens. PCO pregnancies show placental aromatase dysfunction according to previously established research. The two factors of excess insulin combined with decreased aromatase activity operate together to create an over-androgenic fetal condition [5, 10]. Pregnancy test results show higher testosterone values in maternal blood samples that are collected from female newborns through amniocentesis or umbilical vein sampling from PMOS mothers. This evidence supports the Barker hypothesis regarding gene reprogramming of GWAS-identified genes by the prenatal environment [4, 5, 11]. Laboratory research on sheep, mice and monkeys demonstrates the validity of this hypothesis through the production of PMOS symptoms along with altered DNA methylation patterns after the exposure to high prenatal androgen levels [3, 10]. PMOS appears more frequently in individuals whose closest blood relative such as their mother or sister also has the condition which indicates a major influence of family connections. In terms of inheritance patterns. The disease exhibits polygenic inheritance through multiple genes which each have minimal impact on its development. The intricate nature of PMOS inheritance follows a multifactorial pattern which results from genetic predisposition being affected by lifestyle choices combined with dietary patterns and hormonal contact with the environment [16].

Hormonal Imbalances

PMOS displays itself as an irregular combination of medical conditions which creates persistent ovarian problems paired with elevated levels of testosterone. This endocrinological condition stands as the leading hormonal disorder in women and it occurs as the main reason behind irregular menstruation among these women throughout their reproductive years. Research indicates that PMOS occurs in approximately 25% of women who currently experience menstrual cycles. The main hormonal abnormality in PMOS patients stems from excess androgen production and this effect can develop from obesity or insulin resistance conditions which frequently occur with PMOS [17]. PMOS develops through an improper interaction between behavioral elements and environmental factors together with genetic determinants. An enlargement of one or both ovaries represents the typical clinical presentation of PMOS along with increased numbers of inflamed theca cells that produce elevated amounts of androgens. Enzymatic systems creating excess androgen production occur because of their enhanced functional activity in steroid synthesis. Long-term PMOS can cause various metabolic problems and increase cardiovascular risks which include insulin resistance and dyslipidemia together with endothelial dysfunction and elevated serum levels of luteinizing hormone (LH) [18].

Research shows that pathophysiology of polycystic ovarian disease involves abnormalities found in hypothalamic-pituitary-ovarian or adrenal axes. The gonadotrophin-releasing hormone (GnRH) secretion pattern disturbance causes a change in the ratio of LH to FSH released by the body. The elevated ovarian estrogen levels cause an abnormal feedback system that results in increased LH secretion according to [19]. The healthy woman typically experiences LH to FSH ratio levels ranging from 1 to 2. The LH to FSH ratio experiences a serious reversal in polycystic ovary disease patients up to levels that can reach between 2 and 3 measures. Women with polycystic ovary disease do not experience ovulation because elevated LH/FSH ratio prevents this process. Weight loss alongside adjuvant pharmacological therapy stands as the foundation of PMOS treatment practices [20].

Role of Insulin in Androgen Overproduction

One of the hallmark features of PMOS is the overproduction of androgens, such as testosterone, which contributes to many of the characteristic symptoms of the disorder, including hirsutism (excessive hair growth), acne, and scalp thinning. Insulin resistance plays a critical role in this hormonal imbalance. Elevated insulin levels, as a result of insulin resistance, can stimulate the ovaries to produce more androgens. Insulin directly affects the theca cells in the ovaries, which are responsible for androgen production. Under normal conditions, insulin and luteinizing hormone (LH) work together to regulate ovarian androgen production. However, in PMOS, hyperinsulinemia leads to an overactivation of the theca cells, promoting excessive androgen synthesis [21].

In addition to directly stimulating androgen production, insulin resistance can also impair the normal feedback regulation of hormones. Normally, elevated testosterone levels would trigger a feedback loop that reduces the secretion of LH and insulin. However, in PMOS, this feedback mechanism is disrupted, leading to sustained high levels of insulin and androgens. This contributes to the characteristic symptoms of PMOS, such as irregular menstrual cycles, anovulation (lack of ovulation), and infertility. Insulin resistance has profound effects on glucose metabolism. In a healthy individual, insulin helps regulate blood sugar levels by facilitating the uptake of glucose into the cells for energy production. However, in insulin-resistant individuals, the body’s cells are less responsive to insulin, resulting in higher blood glucose levels. To compensate for this, the pancreas produces more insulin, leading to hyperinsulinemia. Over time, this can increase the risk of developing type 2 diabetes, a condition that is more prevalent in women with PMOS [22].

Insulin resistance also affects fat metabolism and distribution in PMOS. Insulin is a key hormone involved in fat storage, and high levels of insulin promote the accumulation of fat, particularly visceral fat, which is fat stored around the abdomen. Visceral fat is particularly concerning because it is associated with an increased risk of cardiovascular disease, metabolic syndrome, and type 2 diabetes. Women with PMOS often have a more centralized fat distribution, with excess fat accumulating around the waist rather than the hips or thighs, a pattern commonly associated with insulin resistance. Insulin resistance and its associated metabolic dysfunction are key contributors to the long-term health risks faced by women with PMOS [23]. Elevated insulin levels not only promote androgen overproduction but also disrupt glucose and fat metabolism, leading to increased risks of obesity, type 2 diabetes, and cardiovascular disease. These metabolic abnormalities create a vicious cycle, where insulin resistance exacerbates symptoms of PMOS and contributes to the development of additional health complications. As a result, managing insulin resistance is a critical component of treating PMOS and improving both metabolic and reproductive health. Treatment strategies, such as lifestyle modifications (e.g., diet and exercise) and medications like metformin, aim to reduce insulin resistance, control androgen levels, and improve glucose metabolism, ultimately helping to manage the symptoms of PMOS and reduce the risk of long-term health issues [24].

Role of Gut Microbiome in the Pathogenesis and Management of PMOS

The human gut microbiome has established itself as an essential regulatory factor for host metabolic and hormonal functions in the past few years. A system of trillions of microorganisms residing in the gastrointestinal tract has recently been identified as a dynamic endocrine and immune organ. Researchers now acknowledge dysbiosis represents a significant factor in PMOS development because they have found rising evidence of gut microbiota composition and functional changes. The biological relationship between PMOS and gut microbiota occurs through the coordinated operation of insulin resistance mechanisms alongside systemic inflammatory responses while controlling androgen production and bile acid behavior. The "gut–ovary axis" concept emerges as an important research topic since scientists recognize the connection between the microbiota in the intestines and reproductive endocrine activity across organs. PMOS affects women by reducing their microbial variety and both decreasing protective bacterial groups like Lactobacillus and Bifidobacterium and increasing pro-inflammatory and LPS-producing bacterial species including Bacteroides and Escherichia/Shigella strains. The microbiome community changes induce permeable intestinal walls which results in endotoxemia while activating inflammatory pathways through toll-like receptor 4 (TLR4). The protracted low-level inflammatory condition contributes to increased insulin resistance and simultaneously affects ovarian steroid production by transforming the hormone conditions in the area [25].

In PMOS patients who exhibit insulin resistance of the central nature this metabolic condition creates reciprocal relationships with intestinal microbial communities. Gut-derived metabolites known as short-chain fatty acids (SCFAs) especially butyrate, propionate, and acetate hold essential responsibility for insulin sensitivity control. böyle metabolitler besin liflarının mayalar aracılığıyla sentezlenir bu metabolitler seyreltici etkide bulunur ve çekici hücre fonksiyonlarını düzenler ve sıkılık nokta proteinlerinin doğru ifadesini sağlayarak mide bariyerini korur [26]. The absence of butyrate and other SCFAs at lower levels within PMOS has been linked to rising insulin resistance and simultaneous development of visceral adiposity together with hepatic steatosis. Moreover, the gut microbiome appears to influence androgen production, a hallmark of PMOS. Certain microbial enzymes such as β-glucuronidase can deconjugate androgens in the gut, potentially increasing their reabsorption into circulation. This microbial-driven recirculation of sex hormones could contribute to the hyperandrogenism observed in PMOS, which in turn further disrupts gut microbiota composition—a cyclical relationship that underscores the bidirectional nature of this axis. These insights have paved the way for innovative, microbiome-targeted interventions aimed at restoring eubiosis and improving clinical outcomes in PMOS patients. Approaches such as probiotic and prebiotic supplementation, dietary modifications favoring high-fiber, low-glycemic foods, and even fecal microbiota transplantation (FMT) have shown preliminary promise in modulating microbial composition and reducing metabolic and endocrine dysfunctions in PMOS [27].

Epigenetic Modifications in PMOS: Potential for Targeted Therapy

Epigenetics refers to heritable changes in gene expression that occur without alterations in the DNA sequence. DNA methylation and histone modification together with non-coding RNA activity form part of these modifications. The modification of genes through epigenetic processes responds to environmental factors and reveals a clear link to the understanding of disease phenotype changes in genetically predisposed individuals. Research shows that epigenetic factors create a vital connection between how external factors interact with PMOS patients' reproductive and metabolic tissues that display altered gene expression patterns. Research studies have established various epigenetic modifications in PMOS women who show alterations in genes related to insulin receptor signaling and androgen synthesis pathway along with inflammatory processes. Research has documented abnormal DNA methylation patterns in two significant genes including CYP19A1 that produces aromatase protein as well as INSR responsible for insulin receptor functionality. The protein modifications diminish their quantities and operational efficiency which results in conditions of both hyperandrogenism and insulin resistance found in persons with PMOS. The process of ovarian steroidogenesis and folliculogenesis becomes disrupted when histone and methylated histone modifications experience alterations [28]. The expression of histone deacetylase (HDAC) differs in PMOS patients while HDAC inhibitors produce therapeutic benefits in animal models which indicates their potential for human treatment applications. Acquisition of PMOS is influenced through epigenetic mechanisms which heavily rely on microRNAs to control non-coding RNA activity. Post-transcriptional regulation of gene expression by small micro RNA molecules displays altered levels in PMOS patients between the ovarian tissue and adipose tissue together with blood elements. MicroRNAs including miR-93, miR-223 and miR-145 control insulin sensitivity and inflammation as well as follicle maturation but their altered expression levels seem to contribute to the reproductive and metabolic defects of PMOS. MicroRNAs demonstrate potential use both as diagnostic biomarkers through non-invasive methods and therapeutic targets in medical research [29]. Several compounds with known epigenetic effects, including metformin, resveratrol, and natural flavonoids, are under investigation for their ability to restore normal gene expression in PMOS-affected tissues. In addition, lifestyle interventions such as diet and exercise have been shown to influence epigenetic profiles, offering practical and non-invasive avenues for improving outcomes in women with PMOS [30].

MicroRNAs as Biomarkers and Therapeutic Targets in PMOS

Besides coding functions microRNAs (miRNAs) function as vital molecules that guide gene expression through post-transcriptional mechanisms. MicroRNAs regulate target messenger RNAs through binding sites in their 3’ untranslated regions to either prevent translation or make the mRNAs vulnerable to degradation. Many biological processes that include metabolism and cell cycle regulation and inflammation and apoptosis function through these molecules. A substantial number of scientific investigations demonstrate that microRNAs act as fundamental elements for the creation and advancement of Polyendocrine Metabolic Ovarian Syndrome (PMOS) [31].

The research on miRNAs in PMOS shows their high potential as diagnostic markers. Research indicates that circulating miRNAs maintain highly stable structures which allows for their detection in biofluids thus presenting themselves as promising non-invasive biomarkers for diagnosis and prognosis. The analysis of particular miRNAs found in blood can help identify PMOS cases at an earlier stage while predicting treatment results and clinical outcomes [32]. In addition to their diagnostic value, miRNAs also offer potential as therapeutic targets. Experimental models have demonstrated that restoring or inhibiting specific miRNAs can influence disease-relevant pathways. For instance, inhibition of miR-93 in preclinical studies has shown improvements in insulin sensitivity and glucose metabolism. Similarly, the delivery of miR-145 mimics has been associated with improved follicular development and ovarian function. These findings indicate that miRNA modulation may offer a novel and precise therapeutic strategy for managing PMOS [33].

Role of GLP-1 Receptor Agonists (e.g., Semaglutide) in Managing PMOS

Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide, have emerged as promising agents in the management of Polyendocrine Metabolic Ovarian Syndrome (PMOS), particularly among women with concurrent obesity and insulin resistance. GLP-1 receptor agonists originated as diabetes medications to manage type 2 diabetes mellitus but they work by improving glucose-dependent insulin release while slowing stomach emptying and reducing appetite and producing weight reduction. Due to their vital role in PMOS pathogenesis professionals are now investigating these agents as potential treatment tools outside glucose management [34]. The benefits of these effects help patients restore their ovulatory cycles and show better results in fertility. The main weight-reducing advantage of GLP-1 receptor agonists also helps obese or overweight women with PMOS achieve better menstrual cycles by lowering their androgen levels independently. Semaglutide represents a long-acting GLP-1 receptor agonist that delivers superior weight reduction results than the previous form liraglutide through subcutaneous injections given just once per week. The clinical trials with women having obesity showed that semaglutide delivered substantial weight loss together with reduced waist measurement and improved metabolic syndrome indicators. The use of semaglutide for treating PMOS in women remains unsupported by extensive randomized controlled trials but available research findings suggest positive effects on body weight management together with improved insulin sensitivity and regular menstrual cycles [35].

Artificial Intelligence in Predicting and Diagnosing PMOS

Polycystic ovary syndrome is a heterogeneous endocrine disorder with varying phenotypes and overlapping symptoms, making early diagnosis and risk prediction particularly challenging. Conventional diagnostic methods rely heavily on clinical assessments, hormonal profiling, and imaging techniques, which are often time-consuming, subjective, and inconsistently applied across clinical settings. In recent years, artificial intelligence has emerged as a powerful tool for enhancing diagnostic accuracy and identifying patterns in complex, multidimensional datasets [36]. Several studies have demonstrated the potential of machine learning algorithms in accurately identifying PMOS from a combination of clinical, biochemical, and radiological parameters. Supervised learning models, such as support vector machines, decision trees, and random forests, have been trained on datasets comprising features such as serum androgen levels, anti-Müllerian hormone, body mass index, insulin resistance indices, and ovarian ultrasound metrics. These models have reported diagnostic accuracies exceeding eighty-five percent in some studies, outperforming traditional rule-based systems. Deep learning models, particularly neural networks, have been employed for image-based diagnosis using transvaginal ultrasound scans. Convolutional neural networks can extract subtle morphological features of polycystic ovaries that may be missed by human observers, enabling objective and reproducible identification of traits such as increased follicle number and ovarian volume. Such image analysis tools may be valuable in resource-limited settings where expert sonographers are not readily available [37].

AI applications help determine the possible future development of PMOS symptoms in groups with risk factors. Longitudinal data review along with lifestyle element study and genetic pattern observation and hormonal changes analysis through artificial intelligence models generates risk prediction metrics or early indicators for preclinical discoveries. Computational models predicting the evolution of PMOS serve as assets for implementing treatment strategies like lifestyle adjustments along with specific therapeutic measures before patients develop permanent consequences including infertility and metabolic syndrome. Medical researchers now apply natural language processing technologies to analyze relevant information which resides in unstructured medical documentation and electronic patient records as well as self-reported outcomes. Through artificial intelligence-driven analysis organizations gain expanded observational abilities to assess PMOS symptomatology along with associated diseases and treatments [38].

Artificial intelligence technology demonstrates wide-ranging value in the management and treatment of PMOS. The technology performs an essential function when defining different types of disorders. Different phenotypes of PMOS exist according to whether patients show signs of hyperandrogenism and ovulatory dysfunction and have polycystic ovarian morphology. The classification of PMOS experiences multiple variations throughout time including patient responses to treatment while current diagnostic systems exhibit low consistency levels. Unsupervised learning techniques enable machine learning methods to create biological patient subtypes. These methods for classification incorporate both clinical factors along with molecular findings and metabolic and behavioral information which helps identify specific PMOS patient groups with exclusive health risks together with individual treatment needs. Studies applying artificial intelligence unified clinical profiles with genomic along with metabolomic data to find various PMOS phenotypes which standard assessment methods do not recognize. Different phenotypic categories could affect how individuals respond to specific medications including metformin and oral contraceptives and lifestyle modifications. Artificial intelligence modeling technology functions as a decision-making tool to create personalized PMOS management strategies based on individual characteristics [39].

Artificial intelligence also contributes to treatment monitoring and optimization. By analyzing real-time data from wearable devices, mobile applications, and digital health platforms, artificial intelligence systems can track lifestyle changes, sleep patterns, physical activity, and symptom progression. These systems can be programmed to provide personalized feedback, recommend behavioral adjustments, or alert healthcare providers when intervention is needed. Remote monitoring capabilities are relevant for managing PMOS, which often requires long-term adherence to lifestyle changes and ongoing metabolic surveillance. Artificial intelligence tools are also being developed for use in reproductive medicine and fertility treatment among women with PMOS. Assisted reproductive technologies often require precise control of ovulation induction and embryo selection. Artificial intelligence algorithms can be used to predict ovarian response to stimulation, forecast the likelihood of oocyte retrieval success, and identify high-quality embryos for transfer. These applications are useful in PMOS patients who are at risk of ovarian hyperstimulation syndrome or poor oocyte quality. Improving prediction accuracy and optimizing treatment protocols may increase the efficiency and safety of fertility care in PMOS [40].

Transgenerational Effects of PMOS: Does the Condition Begin in the Womb?

Polycystic ovary syndrome is a complex endocrine disorder that affects a significant proportion of women of reproductive age. Traditionally, the condition has been associated with post-pubertal hormonal imbalances, metabolic dysfunction, and reproductive irregularities. However, emerging evidence suggests that the origins of PMOS may be established much earlier, possibly during fetal development. The concept that PMOS begins in the womb is increasingly supported by animal studies, human observational data, and epigenetic research, pointing to a developmental and transgenerational dimension of the disorder. One of the central hypotheses regarding the early origins of PMOS is the role of intrauterine androgen exposure. During fetal development, elevated levels of maternal androgens can cross the placenta and influence the differentiation and programming of the fetal hypothalamic-pituitary-ovarian axis. Experimental studies in animals, particularly in rodents and sheep, have shown that prenatal exposure to androgens can lead to features resembling PMOS in the female offspring. These features include disrupted folliculogenesis, hyperandrogenism, insulin resistance, and altered reproductive cycling, which persist into adulthood [41].

Digital CBT (Cognitive Behavioral Therapy) Platforms for PMOS-Related Anxiety & Depression

Digital cognitive behavioral therapy platforms offer an important opportunity to address the unmet psychological needs of women living with polycystic ovary syndrome. While the biological and metabolic components of PMOS have been the primary focus of clinical care, the psychological sequelae—particularly anxiety, depression, low self-esteem, and disordered eating—often remain underdiagnosed and undertreated. These issues can further exacerbate physical symptoms and negatively impact treatment adherence and quality of life. The cyclical relationship between psychological distress and PMOS symptoms highlights the value of early and sustained mental health interventions. Women with PMOS often report feeling misunderstood, frustrated, or isolated due to a lack of clear information and societal awareness about the condition. These emotional burdens can lead to internalized stigma, social withdrawal, and health avoidance behaviors. Cognitive behavioral therapy, with its structured focus on challenging cognitive distortions and building adaptive coping strategies, is well-suited to address such concerns.

Digital platforms delivering CBT content have proliferated in recent years. These range from mobile applications to web-based portals offering interactive modules, digital workbooks, cognitive restructuring tools, relaxation techniques, and guided journaling. Some also incorporate AI-driven personalization features that adapt to user behavior and mood input over time. While many platforms are general-purpose mental health tools, there is a growing recognition of the need for condition-specific modules, including those tailored to reproductive and hormonal health. Initial pilot studies suggest that digital CBT interventions may be particularly effective for managing body dissatisfaction and appearance-related distress in women with PMOS. These emotional responses are often linked to visible symptoms such as acne, hirsutism, and obesity, which can result in significant shame and social anxiety. CBT modules that focus on body image acceptance, mindfulness, and behavioral activation can help users develop healthier relationships with their bodies, thereby reducing appearance-related anxiety [44].

Another area of relevance is the management of emotional eating, binge eating, and loss of control eating, which are more prevalent in PMOS and often associated with insulin resistance and poor metabolic outcomes. Digital CBT platforms can incorporate food diaries, thought logs, and trigger tracking to help users identify patterns of disordered eating and apply cognitive strategies to change them. Some platforms also include gamified reward systems and progress tracking tools that enhance user motivation and program adherence. There is also emerging interest in integrating digital CBT into multidisciplinary PMOS management programs. Combining CBT with digital coaching in nutrition, exercise, and medication adherence has the potential to create a more holistic and sustainable intervention. For example, patients may simultaneously receive dietary advice, set physical activity goals, and address unhelpful thoughts or mood states that interfere with behavioral change. This integrative model reflects the multifaceted nature of PMOS and aligns with best-practice recommendations for comprehensive care [45].

Importantly, the use of digital CBT platforms is associated with reduced care disparities. Women from rural or underserved regions, who may lack access to mental health specialists, can engage in self-guided or supported CBT from the privacy of their homes. For patients experiencing cultural or linguistic barriers, platforms that offer multi-language support and culturally sensitive content are increasingly being developed. Furthermore, asynchronous therapy options reduce scheduling conflicts and eliminate travel time, making care more flexible and accessible. Despite these advantages, there are several limitations and challenges that must be addressed. Engagement rates for digital mental health interventions can be highly variable, and drop-out rates remain a concern, particularly for unguided or text-heavy programs. User-centered design principles are crucial to ensure that interfaces are intuitive, content is engaging, and feedback is timely and relevant. Programs that incorporate therapist or coach check-ins—either via text, video, or chat—tend to maintain higher completion rates and better outcomes [46].

Data security and privacy are additional concerns, especially given the sensitive nature of both reproductive and mental health information. Users must be assured that their data will be stored securely and used ethically [47]. Regulatory oversight and certification of digital mental health tools are still evolving, and not all available platforms meet clinical standards for safety and efficacy. In terms of future directions, there is a need for high-quality clinical trials assessing the effectiveness of digital CBT specifically in the PMOS population. Most existing studies involve general populations with depression or anxiety, and while findings are promising, condition-specific validation is essential. Researchers and developers should collaborate with endocrinologists, gynecologists, psychologists, and patients to design tools that reflect the lived experience of PMOS and its unique psychological profile [48-50].

Future Directions

The future of Polyendocrine Metabolic Ovarian Syndrome (PMOS) management lies in the advancement of personalized medicine, continued research into novel biomarkers and treatments, and a greater focus on understanding the psychosocial aspects of the condition. These directions are critical to improving both the physical and emotional well-being of women with PMOS.

Advances in personalized medicine hold great promise for the management of PMOS. Personalized medicine involves tailoring medical treatments based on an individual's genetic profile, lifestyle, and specific disease characteristics. For PMOS, this approach could lead to more precise and effective treatments by considering the unique hormonal, metabolic, and genetic factors contributing to each patient's condition. For example, genetic testing may help identify specific gene mutations or polymorphisms associated with insulin resistance or androgen overproduction in women with PMOS, allowing for more targeted therapies. Personalized approaches could also improve the use of medications, ensuring that patients receive treatments that are most likely to be effective based on their individual characteristics, reducing side effects and improving outcomes. As research into the genetic and epigenetic underpinnings of PMOS advances, personalized medicine will likely become a cornerstone of treatment, offering more tailored and effective care for women with the condition.

Research into novel biomarkers and treatments for PMOS is also an exciting area of development. Currently, diagnosis and treatment are largely based on clinical features and hormonal assessments, but identifying specific biomarkers for PMOS could lead to earlier and more accurate diagnosis. Biomarkers could also help predict which women are more likely to develop certain complications, such as type 2 diabetes, cardiovascular disease, or endometrial cancer, allowing for more proactive monitoring and intervention. In terms of treatments, there is growing interest in new medications that target specific aspects of PMOS, such as drugs that modulate insulin signaling, reduce ovarian androgen production, or improve ovarian function. GLP-1 agonists, which are currently used for managing type 2 diabetes, show promise for improving insulin sensitivity and aiding in weight management in women with PMOS. Research into other classes of medications, including anti-obesity drugs, will likely offer additional treatment options. Furthermore, novel approaches to fertility treatment, such as gene therapy or stem cell therapy, could provide groundbreaking solutions for women with PMOS who struggle with infertility.

Another crucial aspect of future PMOS research is addressing the gaps in understanding the psychosocial aspects of the condition. While much has been done to understand the physical health impacts of PMOS, more research is needed to explore the emotional, social, and psychological consequences of living with this condition. Women with PMOS often face mental health challenges, including anxiety, depression, and body image issues, which can significantly reduce their quality of life. The stigma associated with symptoms like hirsutism and obesity further exacerbates these challenges. Greater attention must be paid to developing interventions that address the mental health needs of women with PMOS. Research into how PMOS affects relationships, self-esteem, and social interactions will help create more comprehensive care strategies that not only address the physical symptoms of the condition but also provide psychological and emotional support. Integrating mental health care into the overall treatment plan for women with PMOS will ensure that these individuals receive holistic care that improves both their physical and emotional well-being.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a complex and multisystem disorder that affects various aspects of a woman's health, including her reproductive, metabolic, and psychological well-being. Characterized by hormonal imbalances, insulin resistance, ovarian dysfunction, and a range of associated symptoms such as irregular periods, infertility, excessive hair growth, and acne, PMOS is one of the most common endocrine disorders in women of reproductive age. Beyond these reproductive concerns, PMOS is linked to long-term health risks, including cardiovascular disease, type 2 diabetes, endometrial cancer, and psychological challenges such as anxiety and depression. Given the wide-ranging impact of PMOS, it is clear that a holistic approach to diagnosis, treatment, and long-term management is essential. The management of PMOS requires the involvement of multiple healthcare professionals, including endocrinologists, gynecologists, dietitians, mental health professionals, and general practitioners, to address the physical, metabolic, and emotional aspects of the condition. This collaborative, multidisciplinary approach ensures that each patient's unique needs are met, with personalized treatments aimed at improving both physical health and quality of life .

1. Rasquin LI, Anastasopoulou C, Mayrin JV. Polycystic Ovarian Disease. [Updated 2022 Nov 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459251/
2. Zhang C, Ma J, Wang W, Sun Y, Sun K. Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. Hum Reprod. 2018 Nov 1;33(11):2096-2106.
3. Norman RJ, Teede HJ. A new evidence-based guideline for assessment and management of polycystic ovary syndrome. Med J Aust. 2018 Sep 1;209(7):299-300.
4. Goyal A, Ganie MA. Idiopathic hyperprolactinemia presenting as polycystic ovary syndrome in identical twin sisters: a case report and literature review. Cureus. 2018 Jul 19;10(7):e3004.
5. Albu D, Albu A. The relationship between anti-Müllerian hormone serum level and body mass index in a large cohort of infertile patients. Endocrine. 2019 Jan;63(1):157-63.
6. Spinedi E, Cardinali DP. The polycystic ovary syndrome and the metabolic syndrome: a possible chronobiotic-cytoprotective adjuvant therapy. Int J Endocrinol. 2018;2018:1349868.
7. Puttabyatappa M, Padmanabhan V. Ovarian and extra-ovarian mediators in the development of polycystic ovary syndrome. J Mol Endocrinol. 2018 Oct 16;61(4):R161-R184.
8. Hallajzadeh J, Khoramdad M, Karamzad N, Almasi-Hashiani A, Janati A, Ayubi E, et al. Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis. J Cardiovasc Thorac Res. 2018;10(2):56-69.
9. Maya ET, Guure CB, Adanu RMK, Sarfo B, Ntumy M, Bonney EY, et al. Why we need epidemiologic studies of polycystic ovary syndrome in Africa. Int J Gynaecol Obstet. 2018 Nov;143(2):251-4.
10. Carvalho LML, Dos Reis FM, Candido AL, Nunes FFC, Ferreira CN, Gomes KB. Polycystic ovary syndrome as a systemic disease with multiple molecular pathways: a narrative review. Endocr Regul. 2018 Oct 1;52(4):208-21.
11. Marciniak A, Lejman-Larysz K, Nawrocka-Rutkowska J, Brodowska A, Songin D. [Polycystic ovary syndrome - current state of knowledge]. Pol Merkur Lekarski. 2018 Jun 27;44(264):296-301.
12. Sala Elpidio LN, de Alencar JB, Tsuneto PY, Alves HV, Trento Toretta M, It Taura SK, et al. Killer-cell immunoglobulin-like receptors associated with polycystic ovary syndrome. J Reprod Immunol. 2018 Nov;130:1-6.
13. Shorakae S, Ranasinha S, Abell S, Lambert G, Lambert E, de Courten B, et al. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PMOS. Clin Endocrinol (Oxf). 2018 Nov;89(5):628-33.
14. Xie J, Burstein F, Garad R, Teede HJ, Boyle JA. Personalized mobile tool AskPMOS delivering evidence-based quality information about polycystic ovary syndrome. Semin Reprod Med. 2018 Jan;36(1):66-72.
15. Boyle JA, Xu R, Gilbert E, Kuczynska-Burggraf M, Tan B, Teede H, et al. Ask PMOS: identifying need to inform evidence-based app development for polycystic ovary syndrome. Semin Reprod Med. 2018 Jan;36(1):59-65.
16. Misso ML, Tassone EC, Costello MF, Dokras A, Laven J, Moran LJ, et al. Large-scale evidence-based guideline development engaging the international PMOS community. Semin Reprod Med. 2018 Jan;36(1):28-34.
17. Tay CT, Moran LJ, Wijeyaratne CN, Redman LM, Norman RJ, Teede HJ, et al. Integrated model of care for polycystic ovary syndrome. Semin Reprod Med. 2018 Jan;36(1):86-94.
18. Htet T, Cassar S, Boyle JA, Kuczynska-Burggraf M, Gibson-Helm M, Chiu WL, et al. Informing translation: the accuracy of information on websites for lifestyle management of polycystic ovary syndrome. Semin Reprod Med. 2018 Jan;36(1):80-5.
19. Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab. 2014 Jul;99(7):2584-91.

20. Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): a six-month, open-label randomized study. J Clin Endocrinol Metab. 2013 Sep;98(9):3599-607.
21. Glintborg D, Andersen M. Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. Curr Opin Obstet Gynecol. 2017 Dec;29(6):390-6.
22. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018 Sep;89(3):251-68.
23. Gleicher N, Darmon S, Patrizio P, Barad DH. Reconsidering the Polyendocrine Metabolic Ovarian Syndrome (PMOS). Biomedicines. 2022;10:1505. doi:10.3390/biomedicines10071505
24. Yang J, Chen C. Hormonal changes in PMOS. J Endocrinol. 2024;261(1). doi:10.1530/joe-23-0342
25. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110:364–79. doi:10.1016/j.fertnstert.2018.05.004
26. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Clin Pract Endocrinol Metab. 2018;14:270–84. doi:10.1038/nrendo.2018.24
27. De Leo V, Lanzetta D, D’Antona D, la Marca A, Morgante G. Hormonal effects of Flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:99–102. doi:10.1210/jcem.83.1.4500
28. Moghetti P, Castello R, Magnani CM, Tosi F, Negri C, Armanini D, et al. Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab. 1994;79:1115–21. doi:10.1210/jcem.79.4.7962284
29. Castelo-Branco C, Del Pino M. Hepatotoxicity during low-dose Flutamide treatment for hirsutism. Gynecol Endocrinol. 2009;25:419–22. doi:10.1080/09513590902730754
30. Mendoza N, Simoncini T, Genazzani AD. Hormonal contraceptive choice for women with PMOS: a systematic review of randomized trials and observational studies. Gynecol Endocrinol. 2014;30:850–60. doi:10.3109/09513590.2014.943725
31. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with Drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011;183:E1319–25. doi:10.1503/cmaj.110463
32. Belisle S, Love EJ. Clinical efficacy and safety of Cyproterone acetate in severe hirsutism: results of a multicentered Canadian study. Fertil Steril. 1986;46:1015–20. doi:10.1016/S0015-0282(16)49873-0
33. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–92. doi:10.1210/jc.2013-2350
34. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997;3:359–65. doi:10.1093/humupd/3.4.359
35. Pasquali R. Metformin in women with PMOS. Prog Endocr. 2015;48:422–6. doi:10.1007/s12020-014-0311-1
36. Zhang Y, Hu M, Meng F, Sun X, Xu H, Zhang J, et al. Metformin ameliorates uterine defects in a rat model of polycystic ovary syndrome. EBioMedicine. 2017;18:157–70. doi:10.1016/j.ebiom.2017.03.023
37. Xie Y, Xiao L, Li S. Effects of metformin on reproductive, endocrine, and metabolic characteristics of female offspring in a rat model of Letrozole-induced polycystic ovarian syndrome with insulin resistance. Front Endocrinol. 2021;12:701590. doi:10.3389/fendo.2021.701590
38. Tremblay RR. Treatment of hirsutism with spironolactone. Clin Endocrinol Metab. 1986;15:363–71. doi:10.1016/s0300-595x(86)80030-5
39. Sabbadin C, Andrisani A, Zermiani M, Donà G, Bordin L, Ragazzi E, et al. Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. J Endocrinol Investig. 2016;39:1015–21. doi:10.1007/s40618-016-0466-0
40. Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician. 2009;79:671–6.
41. Malik S, Saeed S, Saleem A, Khan MI, Khan A, Akhtar MF. Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs. Front Endocrinol. 2023;14:1294406. doi:10.3389/fendo.2023.1294406
42. Sadeghi Ataabadi M, Alaee S, Bagheri MJ, Bahmanpoor S. Role of essential oil of Mentha spicata (spearmint) in addressing reverse hormonal and folliculogenesis disturbances in a polycystic ovarian syndrome in a rat model. Adv Pharm Bull. 2017;7:651–4. doi:10.15171/apb.2017.078
43. Yang H, Lee SY, Lee SR, Pyun BJ, Kim HJ, Lee YH, et al. Therapeutic effect of Ecklonia cava extract in Letrozole-induced polycystic ovary syndrome rats. Front Pharmacol. 2018;9:1325. doi:10.3389/fphar.2018.01325
44. Rudic J, Jakovljevic V, Jovic N, Nikolic M, Sretenovic J, Mitrovic S, et al. Antioxidative effects of standardized Aronia melanocarpa extract on reproductive and metabolic disturbances in a rat model of polycystic ovary syndrome. Antioxidants. 2022;11:1099. doi:10.3390/antiox11061099
45. Bohlmann J, Keeling CI. Terpenoid biomaterials. Plant J. 2008;54:656–69. doi:10.1111/j.1365-313X.2008.03449.x
46. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-79.
47. Glintborg D, Mumm H, Holst JJ, Andersen M. Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocr Connect. 2017 May;6(4):267-77.
48. Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet. 2016 Mar;293(3):509-15.
49. Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PMOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Aug;39(2):332-42.
50. Yuan, J., Li, Z., Yu, Y., Wang, X., & Zhao, Y. (2025). Natural compounds in the management of polycystic ovary syndrome: A comprehensive review of hormonal regulation and therapeutic potential. Frontiers in Nutrition, 12, 1520695. https://doi.org/10.3389/fnut.2025.1520695.